← Back to Search

Cancer Vaccine

Web-based educational video on pneumococcal vaccination and reminder email to be vaccinated for Pneumonia Vaccine (PROPEL Trial)

N/A

Waitlist Available

Led By Giorgia Sulis, PhD

Research Sponsored by University of Ottawa

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

adults aged ≥ 65 residing in any Canadian province

Reporting not having received a pneumococcal vaccine

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 4-6 months

Awards & highlights

PROPEL Trial Summary

This trial aims to see if a web-based educational video and reminder email can increase pneumococcal vaccine uptake in adults aged 65 or older in Canada who haven't been vaccinated. Participants will fill

Who is the study for?

This trial is for adults aged 65 or older living in Canada who haven't had a pneumococcal vaccine and can understand English or French. It's not for those living in nursing homes.Check my eligibility

What is being tested?

The study tests if a web-based educational video on pneumococcal vaccines plus an email reminder increases vaccine uptake compared to just the email reminder. Participants will fill out surveys before and after the intervention.See study design

What are the potential side effects?

Since this trial focuses on education rather than administering vaccines, there are no direct side effects from the interventions being studied.

PROPEL Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 65 or older and live in Canada.

Select...

I have not received a pneumococcal vaccine.

PROPEL Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 4-6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~4-6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 4-6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Pneumococcal vaccine uptake measured using a web-based follow-up survey four to six months post-randomization

Secondary outcome measures

Change in pneumococcal vaccination willingness, measured using web-based surveys (one at baseline and one four to six months post-randomization)

Change in pneumococcal vaccine attitudes measured using web-based surveys (one at baseline and one four to six months post-randomization)

Change in pneumococcal vaccine knowledge measured using web-based surveys (one at baseline and one four to six months post-randomization)

PROPEL Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Web-based educational video on pneumococcal vaccination and reminder email to be vaccinatedActive Control2 Interventions

Group II: Reminder email to be vaccinatedPlacebo Group1 Intervention

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of OttawaLead Sponsor

205 Previous Clinical Trials

265,305 Total Patients Enrolled

Giorgia Sulis, PhDPrincipal InvestigatorSchool of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available slots for patients to participate in this research study?

"As per clinicaltrials.gov, this particular trial is presently not in search of participants. Initially listed on 1/1/2024 and last revised on 1/22/2024, the study is currently inactive for recruitment. Nonetheless, there are alternative trials available that are actively enrolling patients at present."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Education to Improve Pneumococcal Vaccine Uptake Among Older Adults

2024. "Education to Improve Pneumococcal Vaccine Uptake Among Older Adults". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06234683.